Top of the morning to you, and a busy one it is. This is the midweek mark, after all, and there is much to do. Besides seeing off one of our short people, who is embarking on a journey, we will be hosting a
webinar at 1 pm ET today on salesforce reimbursement effectiveness. Complicating matters, we are terribly behind on our reading. The answer, of course, is a cup of stimulation. Meanwhile, here are some tidbits. Hope your day goes well and stay in touch...Glaxo To Drop Human Genome Bid If Poison Pill Stands (Reuters)
USP And FDA Call For Stricter Heparin Standards (InPharma Technologist)
Statins May Help Prevent Enlarged Prostates: Study (HealthDay)
The Novo Nordisk Quest For An Insulin Pill (Bloomberg News)
European Union Opens Probe Of Parallel Trade (Bloomberg News)
Eli Lilly Releases Mid-Stage Data On GLP-1 Diabetes Med (Pharma Times)
Bill Would Curb Price Gouging On Meds In Short Supply (Associated Press)
FDA Delays Approval For Using Humira To Treat Colitis (Bloomberg News)
A Generic Drugmaker Grows In Uganda (All Africa)
Greek Pharmacists Plan Strike Over Lacks Of Essential Drugs (Pharma Times)
HRT Benefits Outweigh Risks, Review Of Studies Shows (Wall Street Journal)
Neurosearch Denies Charges Of Manipulating Stock (Reuters)
EDITOR'S NOTE: Please check this post for updates during the day
1 Comment